secwatch.observer — SEC 8-K summary
======================================

Issuer:     RVL Pharmaceuticals plc (—)
CIK:        0001739426
Form:       8-K
Filed at:   2023-06-02T23:59:59+00:00
Accession:  0001104659-23-067651
Event type: regulatory
Sentiment:  negative
Materiality: 0.75
Item codes: 3.01
LLM model:  deepseek-v4-flash:cloud@v2

RVL Pharma receives Nasdaq deficiency notice for bid price below $1.00
----------------------------------------------------------------------

- Received Nasdaq deficiency letter on June 2, 2023 for bid price < $1.00 for 30 consecutive business days.
- Has 180 days, until Nov 29, 2023, to regain compliance by closing at $1.00+ for 10 consecutive days.
- May qualify for additional 180-day period by transferring to Nasdaq Capital Market if not cured by Nov 29.
- Company may consider a reverse share split to boost share price, subject to board and shareholder approval.
- No immediate impact on listing; delisting possible if not cured within compliance periods.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1739426/000110465923067651/0001104659-23-067651-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1739426/000110465923067651/tm2317701d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-067651

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer